Related Experiment Video

Updated: Jun 3, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia

Martin Trbusek1, Jitka Malcikova, Jiri Mayer

  • 1Department of Internal Medicine, Hematooncology, University Hospital, Masaryk University, Jihlavska 20, 625 00 Brno, Czech Republic. mtrbusek@fnbrno.cz

Leukemia Research
|March 8, 2011
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Experiment Videos

Last Updated: Jun 3, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Articles linked to this work by shared authors, journal, and citation graph.

Longitudinal single-cell analysis reveals dynamic clonal competition and convergent evolution shaped by therapy sequencing in a young patient with chronic lymphocytic leukemia.

Haematologica·2026

Multilingual Evidence-Based Question-Answering for Stroke Discharge Summaries: Study of Cross-Lingual Heterogeneity in Clinical Reports.

Journal of medical Internet research·2026

Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Haematologica·2026

Multicolor detection of chronic myeloid leukemia stem cells, including novel marker CD69, predicts survival and early hematological toxicity.

Haematologica·2026

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Leukemia·2026

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Leukemia·2026

Circulating NK-cell counts improve prognostic stratification of the PINKE model in extranodal NK/T-cell lymphoma: a retrospective cohort study.

Leukemia research·2026

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Leukemia research·2026

Stemness-driven INTS7 overexpression links metabolic comorbidity to chemoresistance in acute myeloid leukemia with type 2 diabetes.

Leukemia research·2026

SLC1A5 and NUMA1 are potential regulators and therapeutic targets of ferroptosis in diffuse large B-cell lymphoma.

Leukemia research·2026

Feasibility of blinatumomab in newly diagnosed pediatric B-cell acute lymphoblastic leukemia patients requiring modification of standard chemotherapy.

Leukemia research·2026

Treatment outcome in pediatric patients with T-ALL in Brazil.

Leukemia research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us